Memorial Sloan Kettering Westchester

Running trials

• Recruiting

  Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

  NCT07605416· Phase 2· Source

• Recruiting

  A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

  NCT07293247· Phase 2· Source

• Recruiting

  Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

  NCT07215910· Phase 3· Source

• Recruiting

  Malignant Polyp Registry

  NCT07619079· Source

• Recruiting

  Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

  NCT07200830· Phase 3· Source

• Recruiting

  Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

  NCT06900595· Phase 2· Source

• Recruiting

  A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

  NCT07409272· Phase 3· Source

• Recruiting

  Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· Phase 3· Source

• Recruiting

  Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

  NCT06931340· Phase 3· Source

• Recruiting

  Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

  NCT07061977· Phase 3· Source

• Recruiting

  Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  NCT07001748· Phase 2/3· Source

• Recruiting

  Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

  NCT07097142· Phase 3· Source

• Recruiting

  A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

  NCT07209449· Phase 2· Source

• Recruiting

  Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

  NCT06958328· Phase 3· Source

• Recruiting

  Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

  NCT06484062· Phase 1· Source

• Recruiting

  Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

  NCT07000084· Phase 3· Source

• Recruiting

  Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

  NCT06770582· Phase 2· Source

• Recruiting

  Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  NCT06672146· Phase 2· Source

• Recruiting

  Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

  NCT06589804· Phase 3· Source

• Recruiting

  Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  NCT06661720· Phase 3· Source

• Recruiting

  Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  NCT06580314· Phase 3· Source

• Recruiting

  Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

  NCT06500481· Phase 3· Source

• Recruiting

  A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

  NCT06807632· Phase 1· Source

• Active, not recruiting

  A Study of a Weight Loss Intervention in People With Endometrial Cancer

  NCT06751589· Early phase 1· Source

• Active, not recruiting

  Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

  NCT06500455· Phase 3· Source

• Recruiting

  Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  NCT05554406· Phase 2· Source

• Recruiting

  A Study of Sotorasib in People With Non-Small Cell Lung Cancer

  NCT06582771· Phase 2· Source

• Recruiting

  Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  NCT06031688· Phase 2· Source

• Recruiting

  Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

  NCT06022939· Phase 3· Source

• Recruiting

  A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma

  NCT06485778· Phase 2· Source

• Recruiting

  Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

  NCT06205485· Phase 3· Source

• Recruiting

  A Study of Sacituzumab Govitecan in People With Mesothelioma

  NCT06477419· Phase 2· Source

• Active, not recruiting

  A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

  NCT06157892· Phase 2· Source

• Recruiting

  Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

  NCT05987241· Phase 2/3· Source

• Active, not recruiting

  A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders

  NCT06126341· Source

• Active, not recruiting

  A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

  NCT05756777· Phase 1· Source

• Recruiting

  Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

  NCT05673148· Phase 2· Source

• Recruiting

  Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  NCT05624996· Phase 3· Source

• Active, not recruiting

  Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

  NCT05554328· Phase 2· Source

• Recruiting

  Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  NCT05564377· Phase 2· Source

• Recruiting

  Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

  NCT05327686· Phase 2· Source

• Active, not recruiting

  Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

  NCT05610163· Phase 2/3· Source

• Active, not recruiting

  Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

  NCT05256225· Phase 3· Source

• Recruiting

  A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma

  NCT05607095· Phase 1· Source

• Active, not recruiting

  An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues

  NCT05540392· Phase 1/2· Source

• Active, not recruiting

  A Study of Cognitive Health in Survivors of Prostate Cancer

  NCT05540782· Source

• Active, not recruiting

  Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

  NCT05111574· Phase 2· Source

• Recruiting

  A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

  NCT05419076· Phase 2· Source

• Active, not recruiting

  Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

  NCT05092958· Phase 3· Source

• Active, not recruiting

  Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

  NCT05239624· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer12 recruiting
• Colorectal cancer7 recruiting
• Childhood cancers6 recruiting
• Bladder cancer5 recruiting
• Kidney cancer4 recruiting
• Ovarian cancer4 recruiting
• Acute myeloid leukemia3 recruiting
• Endometrial cancer3 recruiting
• Head and neck cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Pancreatic cancer3 recruiting
• Prostate cancer3 recruiting
• Cervical cancer2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Hodgkin lymphoma2 recruiting
• Melanoma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Amyloidosis1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and esophageal cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Mesothelioma1 recruiting
• Multiple myeloma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Sarcoma1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

  NCT05156268· Phase 2· Source

• Completed

  A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma

  NCT05139225· Phase 1· Source

• Completed

  A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

  NCT04965090· Phase 2· Source

• Completed

  A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer

  NCT04905316· Phase 2· Source

• Completed

  Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

  NCT04040231· Phase 1· Source

• Completed

  Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

  NCT03999710· Phase 2· Source

• Completed

  Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

  NCT03939182· Phase 1· Source

• Completed

  A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone

  NCT03909152· Phase 2· Source

• Terminated

  Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

  NCT03199885· Phase 3· Source

• Completed

  Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414· Phase 3· Source

• Completed

  Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

  NCT03810807· Phase 1· Source

• Completed

  A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

  NCT03693807· Phase 2· Source

• Completed

  PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

  NCT03218826· Phase 1· Source

• Completed

  Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer

  NCT03643510· Phase 2· Source

• Completed

  A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

  NCT03532880· Phase 1· Source

• Completed

  A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy

  NCT03542175· Phase 1· Source

• Completed

  Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

  NCT03258554· Phase 2/3· Source

• Completed

  The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

  NCT03295240· Early phase 1· Source

• Completed

  A Study of Nivolumab in Selected Uterine Cancer Patients

  NCT03241745· Phase 2· Source

• Completed

  Proton Re-Irradiation for Recurrent Head and Neck Cancer

  NCT03217188· Phase 2· Source

• Completed

  A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer

  NCT03143270· Early phase 1· Source

• Completed

  Risk Stratification Among Individuals Who Have Many Moles on Their Skin

  NCT03080948· Source

• Completed

  Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

  NCT03026517· Phase 1· Source

• Completed

  Mobile Health Device Study for Myeloma Patients

  NCT03006315· Source

• Completed

  Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

  NCT02101905· Phase 1· Source

• Completed

  High Dose Carfilzomib for Newly Diagnosed Myeloma

  NCT02937571· Phase 1/2· Source

• Completed

  A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

  NCT02819843· Phase 2· Source

• Completed

  AASUR in High Risk Prostate Cancer

  NCT02772588· Phase 2· Source

• Completed

  Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

  NCT02697383· Phase 1· Source

• Completed

  Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer

  NCT02635009· Phase 2/3· Source

• Completed

  Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

  NCT02633137· Phase 2· Source

• Completed

  Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

  NCT02553642· Phase 2· Source

• Completed

  Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  NCT02498600· Phase 2· Source

• Completed

  Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer

  NCT02521363· Source

• Completed

  Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis

  NCT02496585· Phase 2· Source

• Completed

  A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy

  NCT02145871· Phase 3· Source

• Completed

  Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions

  NCT02086578· Phase 2· Source

• Completed

  Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

  NCT01919086· Phase 2· Source

• Completed

  A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

  NCT01908777· Phase 2· Source

• Completed

  Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)

  NCT01862315· Phase 2· Source

• Completed

  Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

  NCT01868451· Source

• Completed

  Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT01767675· Phase 2· Source

• Completed

  Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer

  NCT01312857· Phase 2· Source

• Completed

  Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma

  NCT01261728· Phase 2· Source

• Completed

  Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

  NCT01101451· Phase 3· Source

• Completed

  Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

  NCT01013649· Phase 3· Source

• Completed

  Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy

  NCT01104350· Phase 1· Source

• Completed

  Quality of Life in Patients Undergoing Total Pelvic Exenteration

  NCT00597805· Source